The prevalence of cystic fibrosis (CF) is reported to be approximately 1/2500 in North America and Europe. In our country, according to the results of the newborn screening program launched in 2015, the prevalence was determined to be in the range of 1/7000-9000; however, studies also exist indicating that this rate is higher in some regions. In countries in neighboring geographies, the prevalence is generally around 1/3000-4000.
The number of registered patients followed in Turkey is approximately 2000. However, cystic fibrosis is a disease that can manifest in different age groups and with various clinical findings. It should be noted that there may be patients born before the newborn screening program or those who were not detected during screening. Therefore, it is crucial to thoroughly evaluate patients, especially those presenting with symptoms such as growth and development retardation and recurrent respiratory system infections, for cystic fibrosis.